Life Sciences Tools & Diagnostics: Intra-quarter Pulse Check

In this note, we provide an intra-quarter refresh across our Life Science Tools & Diagnostics coverage universe, updating key datasets, marking-to-market valuation multiples, and revisiting estimates to reflect recent company commentary, conference takeaways, and evolving end-market trends. Macro signals remain broadly constructive, and we continue to see evidence of improving pharma and biotech demand, above historic average monoclonal antibody sales (mAb) volumes, and an inflection in industrial activity, partially offset by weaker NIH funding and a subdued Academic & Government funding environment. Our conversations with investors have been largely focused on MCED regulation and reimbursement milestones, AI-driven laboratory spending trends, the pace of bioprocessing equipment recovery, reshoring trends, and the durability of recent improvements in China and biotech demand.